Boost For Roche, PTV News: Feb 26, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Boost For Roche, PTV News: Feb 26, 2010
Released on: February 26, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Positive results for Avastin from advanced ovarian cancer trial
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Adrian Dawkes
Senior Director, Corporate Advisory
PharmaVentures

Adrian has significant multi-discipline expertise spanning research & development through to sales, marketing and business development from 25 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors. Adrian has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has a BSc in Biochemistry and a PhD in Immunochemistry from Oxford Brookes.
F. Hoffmann-La Roche
F. Hoffmann–La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange.

The company headquarters are located in Basel and the company has many sites around the world - including: Nutley, NJ, Palo Alto, California, Pleasanton, Branchburg, Fishers, Indiana, Florence, South Carolina, Boulder, Colorado and Ponce, Puerto Rico in the US, Welwyn Garden City and Burgess Hill in the UK, Clarecastle in Ireland, Mannheim and Penzberg in Germany, and Shanghai in China.

The company also owns the American biotechnology company Genentech, which is a wholly owned subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals.